Plandai Biotechnology Inc (OTCMKTS:PLPL) Reports USN Formulating New Phytofare Included Products

Plandai Biotechnology Inc (OTCMKTS:PLPL) reported that the sports and wellness group, USN will be preparing more products with Phytofare as ingredient. These products will be launched in the markets of New Zealand and Australia. The products will have green tea catechin-based Phytofare®. USN has accepted the numerous benefits of phyto-availability in order to meet the […]

Plandai Biotechnology Inc (OTCMKTS:PLPL) And Generex Biotechnology Corporation (OTCMKTS:GNBT) Issues Promising PRs

Plandai Biotechnology Inc (OTCMKTS:PLPL) and Generex Biotechnology Corporation (OTCMKTS:GNBT) are the two OTC traded stocks that have been the center of attraction after they issued promising PRs. Plandai reported an amendment to its preciously finalized deal with USN Worldwide. Under the new amended deal with USN, it will now expand its Phytofare® sales to USN […]

Gilead Sciences, Inc. (NASDAQ:GILD) Gaffe Leads Drug Makers To Pledge More Openness On Price

Drug makers are worried about the market reaction over increasing drug prices especially after what happened to Gilead Sciences, Inc. (NASDAQ:GILD) over the Solvadi cure for Hepatitis C. Drug companies such as Sanofi SA (ADR) (NYSE:SNY) and Biogen Inc (NASDAQ:BIIB) expressed their concerns following the undesirable response that Gilead received in 2013. The company had […]

Biogen Idec Inc (NASDAQ:BIIB) And AbbVie Inc (NYSE:ABBV) Reveal Data Confirming Zinbryta Superiority to Avonex in Reducing Annualized Relapse Pace

Boston, MA 09/15/2014 (wallstreetpr) – Global biotech company, Biogen Idec Inc (NASDAQ:BIIB) and research-based pharmaceutical company AbbVie Inc (NYSE:ABBV) disclosed that their Phase three DECIDE clinical study has exhibited a vast improvement in reducing disease activity in people affected by relapsing-remitting multiple sclerosis or RRMS. Phase III Results The companies revealed that the drug candidate, […]

Receptos Inc (NASDAQ:RCPT) To Present Radiance Study Data at MS Boston Conference

Boston, MA 09/11/2014 (wallstreetpr) – Receptos Inc (NASDAQ:RCPT) reported that data from Phase 2/3 trial study of RPC1063 will be reviewed during Oral Podium Presentation on September 13 at MS Boston 2014. It is a grand event where ACTRIMS and ECTRIMS are going to meet on the same platform. It will mark as the largest […]

Receptos Inc (NASDAQ:RCPT) Raising Funds For Product Development

Boston, MA 06/19/2014 (wallstreetpr) – Receptos Inc (NASDAQ:RCPT) has turned to equity offering to raise funds for the development of its lead drug candidate PRC1063 and others. The drug is going through Phase III trial after showing compelling results in its Phase II study. The treatment targets multiple sclerosis (MS). The company has announced offering of […]

Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar Future

Boston, MA 03/19/2014 (wallstreetpr) – Biogen Idec Inc (NASDAQ:BIIB) is a biotechnology pioneer that has invented novel therapies to treat a range of neurodegenerative diseases and autoimmune disorders. Drugs to treat various forms of multiple sclerosis have been the mainstay of the Cambridge, MA-based company for two decades. As global life expectancy continues to increase and […]

Pfizer Inc (NYSE:PFE) Among The Ten To Collaborate With The U.S. Government In Combating America’s Most Prevalent Diseases

Boston, MA 02/06/2014 (wallstreetpr) – Pfizer Inc (NYSE:PFE) is to work with the U.S. government to develop new treatments for some of the most prevalent diseases among Americans. In a $230 million project the government is trying to identify new cure for Alzheimer’s, diabetes, lupus and arthritis. In accordance with the practice of ‘groundbreaking’ at […]